Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

This study is testing a new experimental drug called AGN-INM176 in men with prostate cancer whose PSA (a blood marker for prostate cancer) is rising, to evaluate its safety and effectiveness. **You may be eligible if...** - You are a male aged 40 or older - You have a history of prostate cancer - You have been treated with surgery, radiation, or hormone therapy, OR you have low-risk or intermediate-risk localised prostate cancer that you chose not to treat - You are not currently receiving radiation therapy or hormone therapy (androgen deprivation therapy) - You have good overall health (performance status 0–2) and normal liver and kidney function - You and your partner agree to use two methods of contraception during the study **You may NOT be eligible if...** - You are currently receiving hormone therapy or radiation for prostate cancer - You have abnormal liver, kidney, or blood count results at baseline - You do not meet the study's performance status criteria Talk to your doctor to see if this trial is right for you.